A New Diagnostic Approach Using the NLR / LMR Ratio in the Differential Diagnosis of Neck Masses: Hematologic Evaluation of Patients With Cervical Lymphadenopathy
Open Access
- 29 June 2026
- journal article
- research article
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 40 (15) , e70297
Abstract
Objective: To evaluate the diagnostic utility of hematologic ratios derived from routine complete blood count parameters in differentiating malignant, granulomatous, and reactive cervical lymphadenopathies, with a particular focus on the novel neutrophil‐to‐lymphocyte ratio to lymphocyte‐to‐monocyte ratio (NLR/LMR). Methods: This retrospective study included 406 adult patients who underwent excisional cervical lymph node biopsy between 2015 and 2024 and had histopathologically confirmed diagnoses. Patients were classified into five groups: reactive lymphadenopathy, Hodgkin lymphoma (HL), non‐Hodgkin lymphoma (NHL), granulomatous non‐caseating (Gran–NC), and granulomatous caseating (Gran–C). Pre‐biopsy hematologic parameters (WBC, neutrophil, lymphocyte, monocyte, platelet, RDW) and derived ratios (NLR, LMR, PLR, RDW/PLT, NLR/LMR) were compared among groups. ROC curve analyses were used to assess the diagnostic performance of these parameters in distinguishing lymphoma from non‐lymphoma cases. Results: WBC, neutrophil, monocyte, and RDW levels were significantly higher in lymphoma groups than in reactive and granulomatous groups ( p < 0.001). Among derived ratios, NLR, LMR, PLR, and NLR/LMR demonstrated significant intergroup differences ( p < 0.001). ROC analysis identified NLR (AUC = 0.702, cut‐off = 2.02, OR = 4.92) and NLR/LMR (AUC = 0.707, cut‐off = 0.81, OR = 4.59) as the strongest discriminators for lymphoma. Multivariate logistic regression confirmed both NLR (OR = 1.49, 95% CI 1.24–1.79, p < 0.001) and NLR/LMR (OR = 1.94, 95% CI 1.46–2.57, p < 0.001) as independent predictors of malignancy. Conclusion: Simple hematologic ratios such as NLR and especially the combined index NLR/LMR can serve as reliable, low‐cost, and noninvasive diagnostic indicators for differentiating lymphoma from benign lymphadenopathies. Incorporating these ratios.Keywords
This publication has 17 references indexed in Scilit:
- The role of serum inflammatory markers in determining the severity of cervical lesionsJournal of Obstetrics and Gynaecology Research, 2025
- Neutrophil/Lymphocyte Ratio (NLR) and Lymphocyte/Monocyte Ratio (LMR) – Risk of Death Inflammatory Biomarkers in Patients with COVID-19Journal of Inflammation Research, 2023
- Clinical Significance and Diagnostic Utility of NLR, LMR, PLR and SII in the Course of COVID-19: A Literature ReviewJournal of Inflammation Research, 2023
- The diagnosis and management of suspected lymphoma in general practiceEuropean Journal of Haematology, 2022
- The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies – A Narrative ReviewCancer Management and Research, 2020
- Pre‐treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphomaBritish Journal of Haematology, 2017
- Prognostic role of pretreatment neutrophil-lymphocyte ratio in patients with diffuse large B-cell lymphoma treated with RCHOPMedicine, 2016
- Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysisOncotarget, 2016
- Blood Lymphocyte-to-Monocyte Ratio Identifies High-Risk Patients in Diffuse Large B-Cell Lymphoma Treated with R-CHOPPLOS ONE, 2012
- LymphadenopathyMayo Clinic Proceedings, 2000